MyFinsight
Home
Blog
About
Net increase in
cash, cash...
-$68,335K
(-127.99%↓ Y/Y)
Maturities of marketable
securities
$41,496K
(-21.63%↓ Y/Y)
Share-based compensation
$5,990K
(-36.41%↓ Y/Y)
Accrued
personnel-related expenses,...
$4,684K
(179.14%↑ Y/Y)
Unrecognized tax benefits
$1,333K
(-48.85%↓ Y/Y)
Amortization of right-of-use
assets
$1,076K
(-43.55%↓ Y/Y)
Depreciation and
amortization
$367K
(-55.35%↓ Y/Y)
Other assets
-$331K
(-136.17%↓ Y/Y)
Other
-$26K
(-135.62%↓ Y/Y)
Proceeds from option
exercises
$1,137K
Net cash used in
investing activities
-$60,403K
(-973.64%↓ Y/Y)
Net cash provided by
operating activities
-$6,965K
(-102.77%↓ Y/Y)
Net cash used in
financing activities
-$967K
(28.74%↑ Y/Y)
Canceled cashflow
$41,496K
Canceled cashflow
$13,807K
Canceled cashflow
$1,137K
Purchases of marketable
securities
$101,899K
(74.06%↑ Y/Y)
Net income (loss)
-$5,898K
(-114.30%↓ Y/Y)
Receivables from
collaborative and licensing...
$4,796K
(37.86%↑ Y/Y)
Repurchase of shares to
satisfy tax withholding
$2,104K
(52.80%↑ Y/Y)
Income tax payable
-$3,508K
(-116.83%↓ Y/Y)
Operating lease
liabilities
-$1,935K
(42.46%↑ Y/Y)
something is missing
-$1,779K
Other prepaid and
current assets
$1,252K
(-8.41%↓ Y/Y)
Amortization and accretion on
investment securities, net
$937K
(25.10%↑ Y/Y)
Accounts payable
-$448K
(20.99%↑ Y/Y)
Deferred income taxes
-$218K
(98.26%↑ Y/Y)
Right-of-use lease assets
$1K
(-97.78%↓ Y/Y)
Back
Back
Cash Flow
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)
source: myfinsight.com